Half Year 2026 Valneva SE Earnings Call Transcript
Key Points
- Valneva SE (INRLF) ended the first half of 2026 with a strong cash position of over EUR120 million, bolstered by disciplined cash management and proceeds from a recent offering.
- Pfizer remains highly positive on the Lyme disease vaccine candidate, expecting regulatory decisions within the next 12 months, which could unlock significant value.
- The company has implemented a broad restructuring program expected to generate positive P&L and cash flow impacts in the second half of 2026 and beyond.
- Valneva SE (INRLF) reaffirmed its full-year 2026 guidance for product sales of EUR135-150 million and total revenues of EUR145-160 million, indicating confidence in its base business.
- The locally manufactured Chikungunya vaccine in Brazil by partner Butantan has been approved, with over 50,000 people already vaccinated in a pilot campaign, opening a significant market opportunity.
- The company is advancing its Shigella vaccine candidate, with results from two key studies expected in the coming months, potentially expanding its pipeline.
- Valneva SE (INRLF) reported a significant operating loss of EUR49.9 million in the first half of 2026, a sharp decline from the EUR16.8 million loss in the prior year.
- Total product sales decreased to EUR64 million from EUR91 million in the first half of 2025, driven by distributor transitions, product phasing, and geopolitical factors.
- The company recorded non-recurring charges, including a EUR9.7 million provision for cancellation fees and a EUR4.5 million non-cash impairment of excess inventory, impacting gross margins.
- Gross margins for key products like Ixiaro and Ducoral declined significantly due to lower volumes, manufacturing schedule changes, and higher failed batch costs.
- The future strategic direction and potential for financial self-sustainability are heavily dependent on the successful regulatory approval and commercialization of the Lyme disease vaccine.
- Sales of the Chikungunya vaccine (Ixchiq) remain slow in the travel market, prompting the company to evaluate a strategic shift towards endemic markets.
Good day and thank you for standing by. Bonivo presents its half year 2026 financial results. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session.
To ask a question during the session, you will need to press star one and one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star one and one again.
Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Joshua Drum, VP of Investor Relations. Please go ahead.
Hello, and thank you for joining us to discuss Belneva's financial results for the first half 2026 and corporate update. It's my pleasure to welcome you today.
In addition to our press release and analyst presentation, you can find our consolidated financial results for the six months ended June 30, 2026, which were published earlier today, available
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
